Advertisement
Advertisement
ROIV
Roivant Sciences Ltd. Common Shares
26.45
USDSponsored
-0.30
-1.12%
Feb 13, 16:00 UTC -5
Closed
After-Market
26.75
+0.30
+1.15%
ROIV Earnings Reports
Positive Surprise Ratio
ROIV beat 9 of 18 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Roivant Sciences Ltd. Common Shares earnings per share and revenue
On Feb 06, 2026, ROIV reported earnings of -0.38 USD per share (EPS) for Q3 26, missing the estimate of -0.32 USD, resulting in a -17.28% surprise. Revenue reached 2.00 million, compared to an expected 6.60 million, with a -69.72% difference. The market reacted with a +22.14% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vertex Pharmaceuticals Inc
Report Date
Feb 12, 2026 For Q4 25
Estimate
$5.17
Actual
$5.03
Surprise
-2.79%
Alnylam Pharmaceuticals, Inc.
Report Date
Feb 12, 2026 For Q4 25
Estimate
$1.14
Actual
$0.82
Surprise
-28.48%
Exact Sciences Corp
Report Date
Feb 13, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.38
Surprise
-462.13%
Moderna, Inc. Common Stock
Report Date
Feb 13, 2026 For Q4 25
Estimate
-$2.69
Actual
-$2.11
Surprise
+21.72%
Rezolute, Inc. Common Stock (NV)
Report Date
Feb 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-15.36%
Citius Oncology, Inc. Common Stock
Report Date
Feb 13, 2026 For Q1 26
Estimate
$0.06
Actual
-$0.06
Surprise
-198.04%
Grace Therapeutics, Inc. Common Stock
Report Date
Feb 12, 2026 For Q3 26
Estimate
-$0.28
Actual
-$0.14
Surprise
+50.98%
Anebulo Pharmaceuticals, Inc. Common Stock
Report Date
Feb 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.05
Surprise
+62.29%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Feb 12, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.45
Surprise
+9.22%
Edesa Biotech, Inc. Common Shares
Report Date
Feb 13, 2026 For Q1 26
Estimate
-$0.45
Actual
-$0.28
Surprise
+39.00%
FAQ
What were Roivant Sciences Ltd. Common Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Roivant Sciences Ltd. Common Shares reported EPS of -$0.38, missing estimates by -17.28%, and revenue of $2.00M, -69.72% below expectations.
How did the market react to Roivant Sciences Ltd. Common Shares's Q3 2026 earnings?
The stock price moved up 22.14%, changed from $21.14 before the earnings release to $25.82 the day after.
When is Roivant Sciences Ltd. Common Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Roivant Sciences Ltd. Common Shares's next earnings report?
Based on --
analysts, Roivant Sciences Ltd. Common Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement